Clinical trials: Cancer Disease Progression
Solid Tumor, Adult
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
To determine the recommended phase 2 dose (RP2D) of the combination of neratinib and sodium valproate when given to patients with advanced solid tumors.
- Trial name
- NCT03919292
- Testing
- Neratinib, Divalproex Sodium
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer, Non-Small Cell Lung Cancer
Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
This is a phase II trial of (RQ-07) in advanced solid tumors in prostate, breast or non-small cell lung cancer.
- Conditions
- Prostate Cancer, Non-Small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT02538432
- Testing
- RQ-00000007, Gemcitabine
- Sponsor
- University of Maryland, Baltimore
Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
This was an open-label, phase Ib, multicenter clinical trial to determine the MTD/RDE of the orally administered c-MET inhibitor INC280 in combination with cetuximab.
- Trial name
- NCT02205398
- Testing
- INC280, cetuximab
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
The purpose of this study is to see whether the combination of low-dose Cyclophosphamide and Anti-CTLA4 (Ipilimumab) will stop tumor growth in patients with advanced skin cancer.
- Trial name
- NCT01740401
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Brain Oligometastases
HF-SRT vs. HS-WBRT in Treating Patients With Brain Oligometastases
[Background] For newly-diagnosed patients with brain metastases (BMs), conventional whole-brain radiotherapy (WBRT) might still remain a common palliative management.
- Trial name
- NCT05807165
- Testing
- Hypofractionated Stereotactic Radiotherapy (HF-SRT), Hippocampus-Sparing Whole-Brain Radiotherapy (HS-WBRT) plus memantine
- Where
- Taiwan
- Volunteers
- 115 people
- Sponsor
- Chang Gung Memorial Hospital
Non Small Cell Lung Cancer Metastatic, ALK Gene Mutation
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
This study aims to evaluate the activity and safety of the combination of platinum-pemetrexed based chemotherapy plus Lorlatinib in ALK positive Non-Small Cell Lung Cancer (NSCLC) with exclusively extracranial disease progression…
- Trial name
- ALK-PPL (NCT06378892)
- Testing
- Lorlatinib
- Where
- 9 sites in Italy
- Volunteers
- 45 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Epithelial Ovarian Cancer
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.
The OReO study will be a Phase IIIb, randomised, double-blind, placebo-controlled, multicentre study to assess the efficacy and tolerability of Olaparib retreatment, versus matching placebo, in non-mucinous epithelial ovarian…
- Trial name
- OReO (NCT03106987)
- Testing
- Active Comparator: Olaparib tablets
- Where
- 82 sites in Belgium, Canada and 9 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
Multiple Myeloma
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
Thalidomide-Dexamethasone (TD) is a standard induction therapy for Multiple Myeloma (MM). The present study is designed to compare TD with VELCADE-Thalidomide-Dexamethasone (VTD) as induction therapy in preparation for, and as…
- Trial name
- NCT01134484
- Testing
- Velcade, Thalidomide, Dexamethasone
- Where
- Italy
- Volunteers
- 480 people
- Sponsor
- Michele Cavo
Colorectal Cancer, Liver Metastases
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
Background: Many people with colorectal cancer get liver metastases. Standard treatment for this is a combination of chemotherapy drugs. Directing the chemotherapy to the liver may be effective.
- Conditions
- Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases
- Trial name
- NCT03366155
- Testing
- Codman 3000 constant flow pump catheter, Panitumumab, FUDR-Dex
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Liver Metastases
Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis
For patients with unresectable colorectal cancer liver metastases, preclinical studies have shown that after the resistance of cetuximab, the treatment sensitivity can be restored by stopping cetuximab for a period of time.
- Conditions
- Colorectal Cancer, Liver Metastases, Cetuximab
- Trial name
- NCT04509635
- Testing
- Cetuximab, Chemotherapy
- Volunteers
- 50 people
- Sponsor
- Fudan University
Small Cell Lung Carcinoma (SCLC)
Evaluation of the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC)
[68Ga]Ga-PentixaFor PET-CT will be performed in patients with Small cell lung cancer (SCLC) to confirm the targeting of CXCR4 by [68Ga]Ga-PentixaFor
- Trial name
- PASSIFLORE (NCT07007325)
- Testing
- [68Ga]Ga-PentixaFor
- Where
- 3 sites in France
- Volunteers
- 15 people
- Sponsor
- Institut Cancerologie de l'Ouest
Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only)
The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
Precision oncology has led to a growing population of adults with advanced cancer living increasingly longer lives in the face of profound uncertainty about the future, with over half reporting moderate to high fear of cancer…
- Conditions
- Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only), Glioblastoma, Stage III Ovarian Cancer
- Trial name
- EASE (NCT07636200)
- Testing
- Written Exposure-Based Coping Intervention (EASE), Usual Care Control Condition
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- University of Colorado, Boulder
Breast Cancer
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
The goal of this clinical research study is to find out if adding local therapy (surgery and/or radiation) to standard therapy (chemotherapy or endocrine therapy) in the treatment of patients with metastatic breast cancer can…
- Trial name
- NCT00929214
- Testing
- Standard Therapy, Local Therapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Dysplasia
Can Alternative Treatment Have an Impact on Cervical Dysplasia?
In this study two questions will be answered: can mindfulness meditation help cell-changed on the cervix to disappear? can mindfulness meditation lower the psychological distress when women have abnormal cervical cancer screening…
- Trial name
- NCT00842738
- Testing
- Mindfulness meditation, No meditation, Controls
- Where
- Denmark
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Metastatic Colorectal Cancer
FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation
Single-arm, multi-centre phase II study The primary objective is to evaluate the time to failure of the strategy.
- Trial name
- OPTIPRIME (NCT03584711)
- Testing
- FOLFOX + panitumumab
- Where
- 124 sites in France, Martinique
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Federation Francophone de Cancerologie Digestive
Carcinoma, Basal Cell
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
The primary objective is to estimate the objective response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with cemiplimab as a monotherapy
- Trial name
- NCT03132636
- Testing
- cemiplimab
- Where
- 71 sites in United States, Austria and 8 more
- Volunteers
- 138 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer
SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone
Abiraterone acetate (AA) has shown a favourable impact in overall survival, administered with prednisone to decrease the adverse event related to CYP171A suppression.
- Trial name
- NCT02928432
- Testing
- Steroids switch
- Where
- Spain
- Volunteers
- 26 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Bronchial Neoplasms
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
The aim of this trial is to identify the maximum tolerated dose (MTD)/recommended phase II dose (RP2D), to define pharmacokinetic (PK) parameters and the preliminary efficacy of a continuous treatment with EGF816 and trametinib…
- Trial name
- EATON (NCT03516214)
- Testing
- EGF816, Trametinib
- Where
- 7 sites in Germany, Spain
- Volunteers
- 18 people
- Sponsor
- University of Cologne
Advanced Solid Tumor
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or…
- Trial name
- NCT07070232
- Testing
- BNT326, Pumitamig, Itraconazole
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 1,438 people
- Sponsor
- BioNTech SE
Metastatic Brain Tumors, Progression
Laser Ablation After Stereotactic Radiosurgery
The need for new technologies and devices in the field of neurosurgery is well established. In April 2013, FDA cleared NeuroBlate™ System, minimally invasive robotic laser thermotherapy tool.
- Conditions
- Metastatic Brain Tumors, Progression, Radiation Necrosis, Quality of Life
- Trial name
- LAASR (NCT01651078)
- Where
- 7 sites in United States
- Volunteers
- 44 people
- Sponsor
- Monteris Medical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.